AB0771 HIGH DOSE INTRAVENOUS METHYLPREDNISOLONE INDUCES RAPID IMPROVEMENT OF VISUAL ACUITY IN NON-INFECTIOUS UVEITIS OF DIFFERENT IMMUNE MEDIATED INFLAMMATORY DISEASES
Authors: N. Vegas-Revenga, J. L. Martín-Varillas, V. Calvo-Río, I. González-Mazón, L. Sanchez-Bilbao, E. Beltrán, A. Fonollosa, O. Maiz-Alonso, A. Blanco, M. Cordero-Coma, N. Ortego, I. Torre-Salaberri, F. Francisco, S. Muñoz Fernandez, M. D. M. Esteban-Ortega, M. Díaz-Llopis, J. Cañal, J. A. Ventosa, R. Demetrio-Pablo, L. Domínguez, M. Agudo-Bilbao, S. Castañeda, I. Ferraz-Amaro, M. A. González-Gay, R. Blanco
Journal: Annals of the Rheumatic Diseases (2021)

Background: Rapid and effective remission-inducing therapy is mandatory in uveitis to avoid irreversible structural and functional damage. In some severe cases biological agents might be required (1-6). High-dose intravenous methylprednisolone (IVMP) may achieve prompt control of inflammation in most immune mediated inflammatory diseases (IMID), including non-infectious uveitis (NIU). Objectives: To evaluate the efficacy and safety of IVMP pulse therapy in NIU of different IMID. Methods: Multicentre study of 71 patients with severe uveitis who received IVMP. The underlying diseases were: Vogt Koyanagy Harada disease (VKHD) (n=24), Behçet disease (BD) (19), Sarcoidosis (5) and idiopathic NIU (23). The main outcome variable was Best-Corrected Visual Acuity (BCVA) estimated using the Snellen chart. BCVA that was assessed at 0 (basal), 2-5, 7, 15 and 30 days after IVMP. The results are expressed as mean ±SD in normally distributed variables, or as median [IQR] when are not. Comparison of continuous variables was performed using the Wilcoxon test. Results: We studied 46♀/ 25♂ patients. The main features are shown in Table 1. IVMP dose ranged from 250 to 1000 mg/day administered for 3-5 consecutive days, the dose was established according to the presence or not of other systemic manifestations apart from uveitis. All of them had active intraocular inflammation at the moment of the study. BCVA values improved considerably after 1 month (Figure 1 ). No major side effects were observed. Figure 1. Improvement of best corrected visual acuity (BCVA). Conclusion: High-dose IVMP pulse therapy is useful and safe for a prompt control of BCVA regardless of the underlying IMID. References: [1]Vegas-Revenga N, et al. Am J Ophthalmol. 2019; 200:85-94. doi: 10.1016/j.ajo.2018.12.019 [2]Calvo-Río V, et al. Clin Exp Rheumatol. 2014;32(4 Suppl 84): S54-7. PMID: 25005576 [3]Santos-Gómez M, et al. Clin Exp Rheumatol. 2016;34(6 Suppl 102): S34-S40. PMID:27054359 [4]Atienza-Mateo B, et al. Rheumatology (Oxford) 2018;57(5):856-864. doi: 10.1093/rheumatology/kex480. [5]Atienza-Mateo B, et al. Arthritis Rheumatol. 2019; 71(12):2081-2089. doi: 10.1002/art.41026. [6]Martín-Varillas JL, et al. Ophthalmology. 2018;125(9):1444-1451. doi: 10.1016/j.ophtha.2018.02.020 Table 1. Main features of 71 patients with NIU. Data are of affected eyes. VKHD (n=24 ) Idiophatic (n=23 ) Behcet’s disease (n=19 ) Sarcoidosis (n=5 ) Overall (n=71 ) Men/Women, n 5/19 9/14 9/10 2/3 71 Mean age (years) ±SD 42 ±11 47 ± 15 33±10 42 ± 22 - Unilateral/Bilateral NIU, n (% ) 2 (8.3)/22(91.7) 10 (43.5)/13(56.5) 4 (21)/15 (79) 3(60)/2(40) 19/52 NIU patterns, n (% ) Posterior uveitis 6 (25) 9 (39.1) 3 (15.8) 1 (20) 19 Panuveitis 18 (75) 14 (60.9) 16 (84.2) 4 (80) 52 Laboratory data, n (% ) ANA 2 (8.34) 2 (8.7) 0 (0) 1 (20) 5 HLA B27 0 (0) 4 (17.4) 0 (0) 0 (0) 4 HLA B29 0 (0) 1 (4.3) 0 (0) 0 (0) 1 HLA B51 0 (0) 5 (21.7) 8 (42) 3 (60) 16 Angiotensin Converting Enzyme (ACE) 1 (4.17) 2 (8.7) 0 (0) 1 (20) 4 Disclosure of Interests: None declared